-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Summary
Recessive dystrophic epidermolysis bullosa (RDEB) is a lifelong inherited skin disorder associated with blisters, lesions, and scarring caused by mutations in the COL7A1 gene, which encodes the anchoring fibrous component, collagen VII (C7)
main
Recessive dystrophic epidermolysis bullosa (RDEB) is a devastating rare inherited skin disease with an incidence of 135 per million in the United States
Many early C7 replacement strategies have been evaluated for RDEB8
In vivo direct gene transfer for the treatment of inherited skin diseases has been a long-standing unrealized goal in the field of gene therapy
The large ~9 kb COL7A1 transgene required for RDEB skin correction presents additional challenges for vector engineering
We describe here the development and clinical translation of a localized gene therapy for RDEB that can be reapplied without serious adverse events